Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | ATRNL1 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
mRNA | FAM65A | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
mRNA | MYL6 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
mRNA | GATSL2 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
mRNA | ACSL3 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
mRNA | SYNE3 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
mRNA | PRKRA | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
mRNA | ZFP62 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
mRNA | EXTL3 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
mRNA | RALGAPA2 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |